ArticleAntimicrobial agents and chemotherapy2011
Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods.
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 118 citations in OpenAlex.
- Mg/Mn co-doped CdS nanoparticles: a multifunctional platform for wastewater purification and antibacterial applications.RSC advances · 2026Article
- Synthesis of trifunctional indole-imine-based Ag NPs as a molecular probe for selective colorimetric detection of Cd(ii), photo-catalytic and antimicrobial agent.RSC advances · 2026Article
- Rapid direct disk diffusion testing for antibiotic resistance in urinary tract infections: a bacterial concentration-adjusted approach.Microbiology spectrum · 2025Article
- Isolation, functional characterization and antibiofilm properties of a lytic Enterococcus phage RG1 against multidrug resistant E. faecium.Scientific reports · 2025Article
- Epoxy-Functionalized Isatin Derivative: Synthesis, Computational Evaluation, and Antibacterial Analysis.Antibiotics (Basel, Switzerland) · 2025Article
- Antimicrobial susceptibilities of clinical bacterial isolates from urinary tract infections to fosfomycin and comparator antibiotics determined by agar dilution method and automated micro broth dilution.Microbiology spectrum · 2025Article
- Metabolomics reveals the mechanisms of action of fosfomycin and azithromycin combination in the treatment ofFrontiers in cellular and infection microbiology · 2025Article
- High prevalence of antimicrobial resistance genes in multidrug-resistant-ESBLs-producingIranian journal of microbiology · 2024Article
- Antimicrobial Regimens in Cement Spacers for Periprosthetic Joint Infections: A Critical Review.Antibiotics (Basel, Switzerland) · 2024Review
- Biocompatible antibiotic-coupled nickel-titanium nanoparticles as a potential coating material for biomedical devices.Heliyon · 2024Article
- Antibiotic Resistance to Molecules Commonly Prescribed for the Treatment of Antibiotic-Resistant Gram-Positive Pathogens: What Is Relevant for the Clinician?Pathogens (Basel, Switzerland) · 2024Review
- Fosfomycin susceptibility testing and resistance mechanisms in Enterobacterales in South Africa.African journal of laboratory medicine · 2024Article
- Intravenous Fosfomycin for Systemic Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2023Review
- Plasma and Urine Pharmacokinetics of Oral Fosfomycin Tromethamine in Dogs.Veterinary sciences · 2023Article
- Self-isolation of an Italian long-term care facility during COVID-19 pandemic: A comparison study on care-related infectious episodes.Open medicine (Warsaw, Poland) · 2023Article
- Article
- Differences in Fosfomycin Resistance Mechanisms between Pseudomonas aeruginosa andAntimicrobial agents and chemotherapy · 2022Review
- Synergy Mechanisms of Daptomycin-Fosfomycin Combinations in Daptomycin-Susceptible and -Resistant Methicillin-Resistant Staphylococcus aureus:Antimicrobial agents and chemotherapy · 2022Article
- Glucose-6-phosphate Reduces Fosfomycin Activity AgainstFrontiers in microbiology · 2022Article
- Evaluation of the Synergistic Antibacterial Effects of Fosfomycin in Combination with Selected Antibiotics against Carbapenem-ResistantPharmaceuticals (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We studied the antimicrobial activity of fosfomycin against 960 strains of commonly encountered bacteria associated with urinary tract infection using standard agar dilution and disk diffusion methods. Species studied included 3 common species of Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia; methicillin-susceptible and -resistant Staphylococcus aureus; and vancomycin-susceptible and resistant Enterococcus faecalis and E. faecium. MICs and inhibition zone diameters were interpreted in accordance with both the currently recommended Clinical and Laboratory Standards Institute (CLSI) criteria for urinary tract isolates of Escherichia coli and Enterococcus faecalis and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria for Enterobacteriaceae. Tentative zone diameter interpretive criteria were developed for species not currently published by CLSI or EUCAST. Escherichia coli was uniformly susceptible to fosfomycin, as were most strains of Klebsiella pneumoniae and Enterobacter cloacae. A. baumannii was resistant to fosfomycin, while the prevalence of resistance in P. aeruginosa and S. maltophilia was greatly affected by the choice of MIC breakpoint. New tentative zone diameter criteria for K. pneumoniae, E. cloacae, S. aureus, and E. faecium were able to be set, providing some interim laboratory guidance for disk diffusion until further breakpoint evaluations are undertaken by CLSI and EUCAST.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.